肺癌是全球死亡率最高的癌癥之一，非小細胞肺癌占肺癌總?cè)巳旱?5%以上。約2/3的非小細胞肺癌患者在診斷時已為晚期，內(nèi)科治療是晚期非小細胞肺癌患者的主要治療手段。近些年隨著靶向治療藥物表皮生長因子受體–酪氨酸激酶抑制劑（EGFR-TKI）分子治療的出現(xiàn)，非小細胞肺癌患者的治療取得了明顯的成效。但是EGFR-TKI耐藥問題也接踵而至，總結(jié)了非小細胞肺癌患者EGFR-TKI治療進展以及耐藥后的治療策略，為臨床選擇適合患者個體化治療方案提供參考。

Lung cancer is one of the most lethal cancers in the world. Of them, non-small cell lung cancer (NSCLC) accounts for more than 85% of the total population in China. Almost 2/3 of NSCLC patients are in advanced stage at the time of diagnosis, and medical treatment is the primary/main options for patients with advanced NSCLC. Recently, with the emergence of molecular therapy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI), the treatment of NSCLC has achieved remarkable progression. However, the problem of EGFR-TKI resistance is also coming. This review will summarize the treatment progress of EGFR-TKI in patients with NSCLC and the therapeutic strategies after drug resistance, so as to provide reference for clinical selection of patients with individualized treatment.

R979.1